Menitove J E, Chambers L A, Gjertsonet D W et al. Unexpected Antibodies to Red Cell Antigens and Serologic Crossmatch. In: Gorlin J B, Clegg V, Elliott K, et al.Standards for Blood Banks and Transfusion Services, 21st edition. Bethesda, MD: American Association of Blood Banks (or AABB); 2002. p. 44-45. http://www.dsmanitoba.ca/professionals/transfusion/AABB/STANDARD/STAND21.PDF (accessed on 10th April 2013).
Hillyer CD, Shaz BH, Zimring JC, et al. Pretransfusion Testing. Transfusion Medicine and Hemostasis. Burlington MA: Elsevier, 2009.
Combs MR, Denomme G, Grossman B J, et al. Red Cell antigen-antibody reactions and their detection. In: Brecher ME, Leger RM, Linden JV, et al. Technical Manual, 15th edition. Bethesda, MD: American Association of Blood Banks (or AABB), 2005.p.276-286.http://www.dsmanitoba.ca/professionals/transfusion/AABB/CHAPTR15/chap12.pdf (accessed on 10th April 2013).
Judd WJ, Steiner EA, O'Donnell DB, Oberman HA. Discrepancies in reverse ABO typing due to prozone: How safe is the immediate-spin crossmatch? Transfusiom 1988; 28: 334-8.
Oduola T, Albi O, Adedire A, Aluko O. Low Ionic Strength Solution-Antihuman Globulin Crossmatch: A safer approach to request for uncrossmatched blood. The Internet Journal of Hematology 2006; DOI 10.5580/2605.
Pinkerton PH, Coovadia AS, Goldstein J. Frequency of delayed haemolytic transfusion reactions following antibody screening and immediate-spin crossmatching. Transfusion 1992; 32: 814-7.
Schonewille H, van de Watering L, Loomans D and Brand A. Red blood cell alloantibodies after transfusion: factor influencing incidence and specificity, Transfusion 2006, 46: 250-6.
Weisbach V, Kohnhauser T, Zimmermann R et al. Comparison of the performance of microtube column systems and solid-phase systems and the low- ionic-strength, Transfusion Medicine 2006; 16: 276-84.
Garozzo G, Licitra V, Criscione R, et al. A comparison of two automated methods for the detection and identification of red blood cell alloantibodies. Blood Transfusion 2007; 5: 33-40.
Zakariah AY, Alexander S, van Roosmalen J, et al. Reproductive age mortality survey (RAMOS) in Accra, Ghana. Reprod Health 2009; 6:7-12.
Natukunda B, Schonewille H, Smit Sibinga CT. Assessment of the clinical transfusion practice at a regional referral hospital in Uganda. Transfus Med 2010; 20: 134-139.
Kajja I, Bimenya G, Smit Sibinga C. The interface between blood preparation and use in Uganda. Vox Sang 2010; 98: e257-e262.
Natukunda B, Schonewille H, van de Watering L, Brand A. Prevalence and specificities of red blood cell alloantibodies in transfused Ugandans with different diseases. Vox Sang 2010; 98: 167-171.
Natukunda B, Schonewille H, Ndugwa C, Brand A. Red blood cell alloimmunization in sickle cell disease patients in Uganda. Transfusion 2010; 50: 20-25.
Baby M, Fongoro S, Cissé S, et al. Fréquence de l’allo-immunization érythrocytaire chez les malades polytransfusés au centre hospitalo-universitaire du Point G, Bamako, Mali. Transfus Clin Biol. 2010 Oct; 17: 218-22.
M’baya B, Mfune T, Mogombo E, et al. The prevalence of red cell antigens and antibodies in Malawi. Transfus Med 2010; 20: 196-199.
Meunier N, Rodet M, Bonin P, et al. Study of 206 transfused sickle cell disease patients: immunization, transfusion safety and red blood cell supply. Transfus Clin Biol 2008;15: 377-82.
Tournamille C, Meunier-Costes N, Costes B, et al. Partial C antigen in sickle cell disease patients: clinical relevance and prevention of alloimmunization. Transfusion 2010;50: 2-4.
Norol F, Nadjahi J, Bachir D, et al. Transfusion and alloimmunization in sickle cell anemia patients. Transfus Clin Biol 1994; 1: 27-34.
Bauer MP, Wiersum-Osselton J, Schipperus M, et al. Clinical predictors of alloimmunization after red blood cell transfusion. Transfusion 2007; 47: 2066-71.
Schonewille H, de Vries RR, Brand A. Alloimmune response after additional red blood cell antigen challenge in immunized hematooncology patients. Transfusion 2009; 49: 453-457.
Schonewille H, van de Watering LM, Brand A. Additional red blood cell alloantibodies after blood transfusions in a non hematologic alloimmunized patient cohort: is it time to take precautionary measures? Transfusion 2006; 46: 630-635.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.